The Klein Law Firm
22.7.2021 16:46:59 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / July 22, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
Class Period: November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
Throughout the class period, Frequency Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
Learn about your recoverable losses in FREQ: https://www.kleinstocklaw.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?id=17885&from=1
RLX Technology Inc. (NYSE:RLX)
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline: August 9, 2021
The complaint alleges RLX Technology Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
Learn about your recoverable losses in RLX: https://www.kleinstocklaw.com/pslra-1/rlx-technology-inc-loss-submission-form?id=17885&from=1
Bluecity Holdings Limited (NASDAQ:BLCT)
This lawsuit is on behalf of all persons and entities, other than Defendants, who purchased or otherwise acquired BlueCity American Depositary Shares pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about July 8, 2020.
Lead Plaintiff Deadline: September 17, 2021
Bluecity Holdings Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants had overstated BlueCity's business and financial prospects; (2) the Company was ill-equipped to absorb the costs of becoming a publicly traded company, including IPO- and growth-related costs; (3) as a result of all the foregoing, Defendants had misrepresented the Company's capability for sustainable growth; and (4) as a result, the Offering Documents were materially false or misleading and/or failed to state information required to be stated therein.
Learn about your recoverable losses in BLCT: https://www.kleinstocklaw.com/pslra-1/bluecity-holdings-limited-loss-submission-form?id=17885&from=1
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/656665/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FREQ-RLX-and-BLCT
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release
Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we
Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release
Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging
Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release
Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm
AI Trading Bots Revolutionise Stock, Gold, and Forex Trading: Funds Coin Leads the Move with Guaranteed Profit Option Strategy19.5.2026 14:00:00 CEST | Press release
DENVER, CO / ACCESS Newswire / May 19, 2026 / Forex has always been the world's largest digital financial market in 2026. Now it has become entirely a 24-hour, data-saturated environment. According to the Bank for International Settlements, global OTC foreign exchange turnover reached $9.6 trillion per day in April 2025. This means the foreign exchange turnover was up 28% from 2022. This is a figure that underscores just how deeply connected forex is to global liquidity, risk management, and capital flows. Inside that volume, the competition has intensified dramatically. In 2026, retail traders are no longer competing mainly against other individuals; they are competing against automated systems, and AI-assisted execution engines like Funds Coin. The platform operates across stocks, forex, and financial markets simultaneously. Manual trading, in this environment, is not just inefficient. It is structurally outpaced. Why AI Bots Are Taking Over Forex The following table is provided for
Northfield's Flagship Investment Juno Corp. Discovers Heavy Rare Earth Magnet Metals at Vespa19.5.2026 13:01:00 CEST | Press release
Broadens Juno's Polymetallic Critical Minerals System in Ontario's Ring of Fire TORONTO, ON / ACCESS Newswire / May 19, 2026 / Northfield Capital Corporation ("Northfield" or the "Company") (TSXV:NFD.A) is pleased to comment on the announcement made today by Juno Corp. ("Juno") regarding the discovery of heavy rare earth element ("HREE") mineralization, including the magnet metals neodymium, praseodymium, dysprosium and terbium, within Juno's Vespa critical minerals system in Ontario's Ring of Fire (the "Juno Announcement"). For the full text of the Juno Announcement, including the technical disclosure relating to drill hole VES-26-025 and the associated assay results, please refer to Juno's press release dated May 19, 2026, available at www.junocorp.com. Northfield holds an approximately 35% equity interest in Juno, making Juno one of the most significant investments in Northfield's portfolio. The discovery disclosed in the Juno Announcement broadens the polymetallic critical minerals
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom